Orally Absorbed Cyclic Peptides

Chemical Reviews

Volumn 117, Issue 12, 2017, Pages 8094-8128

  Nielsen, Daniel S ^a   Shepherd, Nicholas E ^a   Xu, Weijun ^a   Lucke, Andrew J ^a,b   Stoermer, Martin J ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CHEMICAL ANALYSIS; CYCLIZATION; DRUG PRODUCTS; HYDROGEN BONDS; LIPIDS; MAMMALS; MOLECULAR WEIGHT; PROTEINS; WATER ABSORPTION;

ACTIVE TRANSPORT; BIOACTIVE CONFORMATION; HYDROGEN BOND DONORS; METABOLIC ENZYMES; OCTANOL-WATER PARTITIONING; ORAL BIOAVAILABILITIES; POLAR SURFACE AREAS; SYSTEMATIC EVALUATION;

PEPTIDES;

CYCLOPEPTIDE;

ABSORPTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION;

ABSORPTION, PHYSICOCHEMICAL; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; HUMANS; PEPTIDES, CYCLIC;

EID: 85021636298     PISSN: 00092665     EISSN: 15206890     Source Type: Journal    
DOI: 10.1021/acs.chemrev.6b00838     Document Type: Review

References (263)

1. Otvos, L., Jr.; Wade, J. D. Current Challenges In Peptide-Based Drug Discovery Front. Chem. 2014, 2 (62) 1-4 10.3389/fchem.2014.00062
2. Clackson, T.; Wells, J. A. A Hot Spot Of Binding Energy In A Hormone-Receptor Interface Science 1995, 267, 383-6 10.1126/science.7529940
3. Moreira, I. S.; Fernandes, P. A.; Ramos, M. J. Hot Spots-A Review Of The Protein-Protein Interface Determinant Amino-Acid Residues Proteins: Struct., Funct., Genet. 2007, 68, 803-12 10.1002/prot.21396
4. Hall, D. R.; Kozakov, D.; Whitty, A.; Vajda, S. Lessons From Hot Spot Analysis For Fragment-Based Drug Discovery Trends Pharmacol. Sci. 2015, 36, 724-36 10.1016/j.tips.2015.08.003
5. Sheng, C.; Dong, G.; Miao, Z.; Zhang, W.; Wang, W. State-Of-The-Art Strategies For Targeting Protein-Protein Interactions By Small-Molecule Inhibitors Chem. Soc. Rev. 2015, 44, 8238-8259 10.1039/C5CS00252D
6. Modell, A. E.; Blosser, S. L.; Arora, P. S. Systematic Targeting Of Protein-Protein Interactions Trends Pharmacol. Sci. 2016, 37, 702-713 10.1016/j.tips.2016.05.008
7. Giannis, A.; Kolter, T. Peptidomimetics For Receptor Ligands-Discovery, Development, And Medical Perspectives Angew. Chem., Int. Ed. Engl. 1993, 32, 1244-1267 10.1002/anie.199312441
8. Fairlie, D. P.; Abbenante, G.; March, D. R. Macrocyclic Peptidomimetics-Forcing Peptides Into Bioactive Conformations Curr. Med. Chem. 1995, 2, 654-686
9. Hruby, V. J. Designing Peptide Receptor Agonists And Antagonists Nat. Rev. Drug Discovery 2002, 1, 847-858 10.1038/nrd939
10. Tyndall, J. D. A.; Pfeiffer, B.; Abbenante, G.; Fairlie, D. P. Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands With Turn Structure Chem. Rev. 2005, 105, 793-826 10.1021/cr040689g
11. Walensky, L. D.; Bird, G. H. Hydrocarbon-Stapled Peptides: Principles, Practice, And Progress J. Med. Chem. 2014, 57, 6275-6288 10.1021/jm4011675
12. Azzarito, V.; Long, K.; Murphy, N. S.; Wilson, A. J. Inhibition Of A-Helix-Mediated Protein-Protein Interactions Using Designed Molecules Nat. Chem. 2013, 5, 161-173 10.1038/nchem.1568
13. Hill, T. A.; Shepherd, N. E.; Diness, F.; Fairlie, D. P. Constraining Cyclic Peptides To Mimic Protein Structure Motifs Angew. Chem., Int. Ed. 2014, 53, 13020-13041 10.1002/anie.201401058
14. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental And Computational Approaches To Estimate Solubility And Permeability In Drug Discovery And Development Settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
15. Lipinski, C. A. Lead- And Drug-Like Compounds: The Rule-Of-Five Revolution Drug Discovery Today: Technol. 2004, 1, 337-341 10.1016/j.ddtec.2004.11.007
16. Leeson, P. D.; Springthorpe, B. The Influence Of Drug-Like Concepts On Decision-Making In Medicinal Chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
17. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence The Oral Bioavailability Of Drug Candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
18. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The Future Of Peptide-Based Drugs Chem. Biol. Drug Des. 2013, 81, 136-147 10.1111/cbdd.12055
19. Nisen, M. The Best Selling Prescription Drugs In The World Last Year. Gen. Eng. Biotechnol. News 2015, Feb 25, https://qz.com/349929/Best-Selling-Drugs-In-The-World/.
20. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic Therapeutic Peptides: Science And Market Drug Discovery Today 2010, 15, 40-56 10.1016/j.drudis.2009.10.009
21. Rowland, M.; Tozer, T. N. Clinical Pharmacokinetics: Concepts And Applications; 3 rd ed.; Williams & Wilkins: Baltimore, MD, 1995.
22. Rubio-Aliaga, I.; Daniel, H. Peptide Transporters And Their Roles In Physiological Processes And Drug Disposition Xenobiotica 2008, 38, 1022-1042 10.1080/00498250701875254
23. Giacomini, K. M.; Huang, S.-M.; Tweedie, D. J. et al. The International Transporter Consortium. Membrane Transporters In Drug Development Nat. Rev. Drug Discovery 2010, 9, 215-236 10.1038/nrd3028
24. Brandsch, M. Drug Transport Via The Intestinal Peptide Transporter PEPT1 Curr. Opin. Pharmacol. 2013, 13, 881-887 10.1016/j.coph.2013.08.004
25. Hillgren, K. M.; Keppler, D.; Zur, A. A.; Giacomini, K. M.; Stieger, B.; Cass, C. E.; Zhang, L. Emerging Transporters Of Clinical Importance: An Update From The International Transporter Consortium Clin. Pharmacol. Ther. 2013, 94, 52-63 10.1038/clpt.2013.74
26. Li, X.; Yu, M.; Fan, W.; Gan, Y.; Hovgaard, L.; Yang, M. Orally Active-Targeted Drug Delivery Systems For Proteins And Peptides Expert Opin. Drug Delivery 2014, 11, 1435-1447 10.1517/17425247.2014.924500
27. Bhutia, Y. D.; Babu, E.; Ramachandran, S.; Yang, S.; Thangaraju, M.; Ganapathy, V. SLC Transporters As A Novel Class Of Tumour Suppressors: Identity, Function And Molecular Mechanisms Biochem. J. 2016, 473, 1113-1124 10.1042/BJ20150751
28. Boll, M.; Markovich, D.; Weber, W. M.; Korte, H.; Daniel, H.; Murer, H. Expression Cloning Of A cDNA From Rabbit Small Intestine Related To Proton-Coupled Transport Of Peptides, Beta-Lactam Antibiotics And Ace-Inhibitors Pfluegers Arch. 1994, 429, 146-149 10.1007/BF02584043
29. Dietrich, C. G.; Geier, A.; Oude Elferink, R. P. J. ABC Of Oral Bioavailability: Transporters As Gatekeepers In The Gut Gut 2003, 52, 1788-1795 10.1136/gut.52.12.1788
30. Lown, K. S.; Mayo, R. R.; Leichtman, A. B.; Hsiao, H. L.; Turgeon, D. K.; Schmiedlin-Ren, P.; Brown, M. B.; Guo, W.; Rossi, S. J.; Benet, L. Z. et al. Pharmacokinetics And Drug Disposition: Role Of Intestinal P-Glycoprotein (MDR1) In Interpatient Variation In The Oral Bioavailability Of Cyclosporine Clin. Pharmacol. Ther. 1997, 62, 248-260 10.1016/S0009-9236(97)90027-8
31. Schinkel, A. H.; Jonker, J. W. Mammalian Drug Efflux Transporters Of The Atp Binding Cassette (ABC) Family: An Overview Adv. Drug Delivery Rev. 2003, 55, 3-29 10.1016/S0169-409X(02)00169-2
32. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay In The Description Of Passive Absorption Processes J. Med. Chem. 1998, 41, 1007-1010 10.1021/jm970530e
33. Hidalgo, T. J.; Raub, T. J.; Borchardt, R. T. Characterization Of The Human Colon Carcinoma Cell Line (CACO-2) As A Model System For Intestinal Epithelial Permeability Gastroenterology 1989, 96, 736-749 10.1016/0016-5085(89)90897-4
34. Press, B.; Di Grandi, D. Permeability For Intestinal Absorption: CACO-2 Assay And Related Issues Curr. Drug Metab. 2008, 9, 893-900 10.2174/138920008786485119
35. Gaush, C. R.; Hard, W. L.; Smith, T. F. Characterization Of An Established Line Of Canine Kidney Cells (MDCK) Exp. Biol. Med. 1966, 122, 931-935 10.3181/00379727-122-31293
36. Rabito, C. A.; Tchao, R.; Valentich, J.; Leighton, J. Distribution And Characteristics Of The Occluding Junctions In A Monolayer Of A Cell Line (MDCK) Derived From Canine Kidney J. Membr. Biol. 1978, 43, 351-365 10.1007/BF01871696
37. Cereijido, M.; Robbins, E. S.; Dolan, W. J.; Rotunno, C. A.; Sabatini, D. D. Polarized Monolayers Formed By Epithelial Cells On A Permeable And Translucent Support J. Cell Biol. 1978, 77, 853-880 10.1083/jcb.77.3.853
38. Misfeldt, D. S.; Hamamoto, S. T.; Pitelka, D. R. Transepithelial Transport In Cell Culture Proc. Natl. Acad. Sci. U. S. A. 1976, 73, 1212-1216 10.1073/pnas.73.4.1212
39. Leighton, J.; Estes, L. W.; Mansukhani, S.; Brada, Z. A Cell Line Derived From Normal Dog Kidney (Mdck) Exhibiting Qualities Of Papillary Adenocarcinoma And Of Renal Tubular Epithelium Cancer 1970, 26, 1022-1028 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M
40. Lodish, H., et al., In Mol. Cell. Biol.; 4 th ed.; Freeman, W. H.: New York, 2000.
41. Frömter, E.; Diamond, J. Route Of Passive Ion Permeation In Epithelia Nat. New Biol. 1972, 235, 9-13 10.1038/newbio235009a0
42. Goh, L. B.; Spears, K. J.; Yao, D.; Ayrton, A.; Morgan, P.; Roland Wolf, C.; Friedberg, T. Endogenous Drug Transporters In In Vitro And In Vivo Models For The Prediction Of Drug Disposition In Man Biochem. Pharmacol. 2002, 64, 1569-1578 10.1016/S0006-2952(02)01355-2
43. Volpe, D. A. Drug-Permeability And Transporter Assays In CACO-2 And MDCK Cell Lines Future Med. Chem. 2011, 3, 2063-2077 10.4155/fmc.11.149
44. Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y.; Federico, J. J.; Davidson, R. E.; Smith, R. et al. Development Of A New Permeability Assay Using Low-Efflux Mdckii Cells J. Pharm. Sci. 2011, 100, 4974-4985 10.1002/jps.22674
45. Chatterjee, J.; Gilon, C.; Hoffman, A.; Kessler, H. N-Methylation Of Peptides: A New Perspective In Medicinal Chemistry Acc. Chem. Res. 2008, 41, 1331-1342 10.1021/ar8000603
46. Bockus, A. T.; Mcewen, C. M.; Lokey, R. S. Form And Function In Cyclic Peptide Natural Products: A Pharmacokinetic Perspective Curr. Top. Med. Chem. 2013, 13, 821-836 10.2174/1568026611313070005
47. Whitty, A.; Zhong, M.; Viarengo, L.; Beglov, D.; Hall, D. R.; Vajda, S. Quantifying The Chameleonic Properties Of Macrocycles And Other High-Molecular-Weight Drugs Drug Discovery Today 2016, 21, 712-717 10.1016/j.drudis.2016.02.005
48. Over, B.; Mccarren, P.; Artursson, P.; Foley, M.; Giordanetto, F.; Gronberg, G.; Hilgendorf, C.; Lee, M. D.; Matsson, P.; Muncipinto, G. et al. Impact Of Stereospecific Intramolecular Hydrogen Bonding On Cell Permeability And Physicochemical Properties J. Med. Chem. 2014, 57, 2746-2754 10.1021/jm500059t
49. Over, B.; Matsson, P.; Tyrchan, C.; Artursson, P.; Doak, B. C.; Foley, M. A.; Hilgendorf, C.; Johnston, S. E.; Lee, M. D. T.; Lewis, R. J. et al. Structural And Conformational Determinants Of Macrocycle Cell Permeability Nat. Chem. Biol. 2016, 12, 1065-1074 10.1038/nchembio.2203
50. Wang, C. K.; Craik, D. J. Cyclic Peptide Oral Bioavailability: Lessons From The Past Biopolymers 2016, 106, 901-909 10.1002/bip.22878
51. Ussing, H. H.; Zerahn, K. Active Transport Of Sodium As The Source Of Electric Current In The Short-Circuited Isolated Frog Skin Acta Physiol. Scand. 1951, 23, 110-127 10.1111/j.1748-1716.1951.tb00800.x
52. Kato, Y.; Miyazaki, T.; Kano, T.; Sugiura, T.; Kubo, Y.; Tsuji, A. Involvement Of Influx And Efflux Transport Systems In Gastrointestinal Absorption Of Celiprolol J. Pharm. Sci. 2009, 98, 2529-2539 10.1002/jps.21618
53. Clarke, L. L. A Guide To Ussing Chamber Studies Of Mouse Intestine Am. J. Physiol.-Gastr. L. 2009, 296, G1151-G1166 10.1152/ajpgi.90649.2008
54. Forner, K.; Roos, C.; Dahlgren, D.; Kesisoglou, F.; Konerding, M. A.; Mazur, J.; Lennernäs, H.; Langguth, P. Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs Drug Dev. Ind. Pharm. 2017, 43, 338-346 10.1080/03639045.2016.1251449
55. Dietrich, C. G.; De Waart, D. R.; Ottenhoff, R.; Schoots, I. G.; Elferink, R. P. J. O. Increased Bioavailability Of The Food-Derived Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-B]Pyridine In MRP2-Deficient Rats Mol. Pharmacol. 2001, 59, 974-980
56. Guengerich, F. P. Cytochrome P450 And Chemical Toxicology Chem. Res. Toxicol. 2008, 21, 70-83 10.1021/tx700079z
57. Park, K.; Kwon, I. C.; Park, K. Oral protein Delivery: Current Status and Future Prospect React. Funct. Polym. 2011, 71, 280-287 10.1016/j.reactfunctpolym.2010.10.002
58. Lee, E.; Lee, J.; Jon, S. A Novel Approach To Oral Delivery Of Insulin By Conjugating With Low Molecular Weight Chitosan Bioconjugate Chem. 2010, 21, 1720-1723 10.1021/bc100093v
59. Henriksen, K.; Bay-Jensen, A. C.; Christiansen, C.; Karsdal, M. A. Oral Salmon Calcitonin-Pharmacology In Osteoporosis Expert Opin. Biol. Ther. 2010, 10, 1617-1629 10.1517/14712598.2010.526104
60. Aungst, B. J. Absorption Enhancers: Applications and Advances AAPS J. 2012, 14, 10-18 10.1208/s12248-011-9307-4
61. Renukuntla, J.; Vadlapudi, A. D.; Patel, A.; Boddu, S. H.; Mitra, A. K. Approaches for Enhancing Oral Bioavailability of Peptides and Proteins Int. J. Pharm. 2013, 447, 75-93 10.1016/j.ijpharm.2013.02.030
62. Fox, C. B.; Kim, J.; Le, L. V.; Nemeth, C. L.; Chirra, H. D.; Desai, T. A. Micro/nanofabricated Platforms for Oral Drug Delivery J. Controlled Release 2015, 219, 431-444 10.1016/j.jconrel.2015.07.033
63. Bak, A.; Leung, D.; Barrett, S. E.; Forster, S.; Minnihan, E. C.; Leithead, A. W.; Cunningham, J.; Toussaint, N.; Crocker, L. S. Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Delivery-A Primer AAPS J. 2015, 17, 144-155 10.1208/s12248-014-9688-2
64. Giordanetto, F.; Kihlberg, J. Macrocyclic Drugs And Clinical Candidates: What Can Medicinal Chemists Learn From Their Properties? J. Med. Chem. 2014, 57, 278-295 10.1021/jm400887j
65. Doak, B. C.; Over, B.; Giordanetto, F.; Kihlberg, J. Oral Druggable Space Beyond The Rule Of 5: Insights From Drugs And Clinical Candidates Chem. Biol. 2014, 21, 1115-1142 10.1016/j.chembiol.2014.08.013
66. Matsson, P.; Doak, B. C.; Over, B.; Kihlberg, J. Cell Permeability Beyond The Rule Of 5 Adv. Drug Delivery Rev. 2016, 101, 42-61 10.1016/j.addr.2016.03.013
67. Matsson, P.; Kihlberg, J. How Big Is Too Big for Cell Permeability? J. Med. Chem. 2017, 60, 1662-1664 10.1021/acs.jmedchem.7b00237
68. Santos, G. B.; Ganesan, A.; Emery, F. S. Oral Administration Of Peptide-Based Drugs: Beyond Lipinski's Rule ChemMedChem 2016, 11, 2245-2251 10.1002/cmdc.201600288
69. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation Of Molecular Polar Surface Area As A Sum Of Fragment-Based Contributions And Its Application To The Prediction Of Drug Transport Properties J. Med. Chem. 2000, 43, 3714-3717 10.1021/jm000942e
70. Aldrich, J. V.; Senadheera, S. N.; Ross, N. C.; Ganno, M. L.; Eans, S. O.; Mclaughlin, J. P. The Macrocyclic Peptide Natural Product CJ-15,208 Is Orally Active And Prevents Reinstatement Of Extinguished Cocaine-Seeking Behavior J. Nat. Prod. 2013, 76, 433-438 10.1021/np300697k
71. Shin, B. S.; Chang, H. S.; Park, E. H.; Yoon, C. H.; Kim, H. Y.; Kim, J.; Ryu, J. K.; Zee, O. P.; Lee, K. C.; Cao, D. et al. Pharmacokinetics Of A Novel Histone Deacetylase Inhibitor, Apicidin, In Rats Biopharm. Drug Dispos. 2006, 27, 69-75 10.1002/bdd.485
72. Stähelin, H.; Trippmacher, A. Cytostatic Activity Of Chlamydocin, A Rapidly Inactivated Cyclic Tetrapeptide Eur. J. Cancer 1974, 10, 801-808 10.1016/0014-2964(74)90137-6
73. Kranz, M.; Murray, P. J.; Taylor, S.; Upton, R. J.; Clegg, W.; Elsegood, M. R. J. Solution, Solid Phase And Computational Structures Of Apicidin And Its Backbone-Reduced Analogs J. Pept. Sci. 2006, 12, 383-388 10.1002/psc.738
74. Namatame, I.; Tomoda, H.; Ishibashi, S.; Omura, S. Antiatherogenic Activity Of Fungal Beauveriolides, Inhibitors Of Lipid Droplet Accumulation In Macrophages Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 737-742 10.1073/pnas.0307757100
75. Hurevich, M.; Swed, A.; Joubran, S.; Cohen, S.; Freeman, N. S.; Britan-Rosich, E.; Briant-Longuet, L.; Bardy, M.; Devaux, C.; Kotler, M. et al. Rational Conversion Of Noncontinuous Active Region In Proteins Into A Small Orally Bioavailable Macrocyclic Drug-Like Molecule: The HIV-1 CD4:Gp120 Paradigm Bioorg. Med. Chem. 2010, 18, 5754-5761 10.1016/j.bmc.2010.04.053
76. Burcham, D. L.; Aungst, B. A.; Hussain, M.; Gorko, M. A.; Quon, C. Y.; Huang, S. M. The Effect Of Absorption Enhancers On The Oral Absorption Of The GP IIb/IIIa Receptor Antagonist, Dmp 728, In Rats And Dogs Pharm. Res. 1995, 12, 2065-2070 10.1023/A:1016289200422
77. Terao, K.; Ito, E.; Tatsuno, T. Liver Injuries Induced By Cyclochlorotine Isolated From Penicillium Islandicum Arch. Toxicol. 1984, 55, 39-46 10.1007/BF00316584
78. Uraguchi, K.; Saito, M.; Noguchi, Y.; Takahashi, K.; Enomoto, M. Chronic Toxicity And Carcinogenicity In Mice Of The Purified Mycotoxins, Luteoskyrin And Cyclochlorotine Food Cosmet. Toxicol. 1972, 10, 193-207 10.1016/S0015-6264(72)80197-4
79. Xu, H.-M.; Zeng, G.-Z.; Zhou, W.-B.; He, W.-J.; Tan, N.-H. Astins K-P Six New Chlorinated Cyclopentapeptides From Aster Tataricus Tetrahedron 2013, 69, 7964-7969 10.1016/j.tet.2013.07.006
80. Shen, Y.; Luo, Q.; Xu, H. M.; Gong, F. Y.; Zhou, X. B.; Sun, Y.; Wu, X. F.; Liu, W.; Zeng, G. Z.; Tan, N. H. et al. Mitochondria-Dependent Apoptosis Of Activated T Lymphocytes Induced By Astin C, A Plant Cyclopeptide, For Preventing Murine Experimental Colitis Biochem. Pharmacol. 2011, 82, 260-268 10.1016/j.bcp.2011.04.013
81. Cummings, D. E.; Schwartz, M. W. Melanocortins And Body Weight: A Tale Of Two Receptors Nat. Genet. 2000, 26, 8-9 10.1038/79223
82. Hess, S.; Linde, Y.; Ovadia, O.; Safrai, E.; Shalev, D. E.; Swed, A.; Halbfinger, E.; Lapidot, T.; Winkler, I.; Gabinet, Y. et al. Backbone Cyclic Peptidomimetic Melanocortin-4 Receptor Agonist As A Novel Orally Administrated Drug Lead For Treating Obesity J. Med. Chem. 2008, 51, 1026-1034 10.1021/jm701093y
83. Chan, K. K.; Bakhtiar, R.; Jiang, C. Depsipeptide (FR901228, Nsc-630176) Pharmacokinetics In The Rat By LC/MS/MS Invest. New Drugs 1997, 15, 195-206 10.1023/A:1005847703624
84. Lai, M.-T.; Yang, C.-C.; Lin, T.-Y.; Tsai, F.-J.; Chen, W.-C. Depsipeptide (FK228) Inhibits Growth Of Human Prostate Cancer Cells Urol. Oncol: Sem. Orig. Invest. 2008, 26, 182-189 10.1016/j.urolonc.2007.01.020
85. Taori, K.; Paul, V. J.; Luesch, H. Structure And Activity Of Largazole, A Potent Antiproliferative Agent From The Floridian Marine Cyanobacterium Symploca SP J. Am. Chem. Soc. 2008, 130, 1806-1807 10.1021/ja7110064
86. Bowers, A.; West, N.; Taunton, J.; Schreiber, S. L.; Bradner, J. E.; Williams, R. M. Total Synthesis And Biological Mode Of Action Of Largazole: A Potent Class I Histone Deacetylase Inhibitor J. Am. Chem. Soc. 2008, 130, 11219-11222 10.1021/ja8033763
87. Bowers, A. A.; Greshock, T. J.; West, N.; Estiu, G.; Schreiber, S. L.; Wiest, O.; Williams, R. M.; Bradner, J. E. Synthesis And Conformation-Activity Relationships Of The Peptide Isosteres Of Fk228 And Largazole J. Am. Chem. Soc. 2009, 131, 2900-2905 10.1021/ja807772w
88. Ghosh, A. K.; Kulkarni, S. Enantioselective Total Synthesis Of (+)-Largazole, A Potent Inhibitor Of Histone Deacetylase Org. Lett. 2008, 10, 3907-3909 10.1021/ol8014623
89. Nasveschuk, C. G.; Ungermannova, D.; Liu, X.; Phillips, A. J. A Concise Total Synthesis Of Largazole, Solution Structure, And Some Preliminary Structure Activity Relationships Org. Lett. 2008, 10, 3595-3598 10.1021/ol8013478
90. Seiser, T.; Kamena, F.; Cramer, N. Synthesis And Biological Activity Of Largazole And Derivatives Angew. Chem., Int. Ed. 2008, 47, 6483-6485 10.1002/anie.200802043
91. Ying, Y.; Taori, K.; Kim, H.; Hong, J.; Luesch, H. Total Synthesis And Molecular Target Of Largazole, A Histone Deacetylase Inhibitor J. Am. Chem. Soc. 2008, 130, 8455-8459 10.1021/ja8013727
92. Cole, K. E.; Dowling, D. P.; Boone, M. A.; Phillips, A. J.; Christianson, D. W. Structural Basis Of The Antiproliferative Activity Of Largazole, A Depsipeptide Inhibitor Of The Histone Deacetylases J. Am. Chem. Soc. 2011, 133, 12474-12477 10.1021/ja205972n
93. Decroos, C.; Clausen, D. J.; Haines, B. E.; Wiest, O.; Williams, R. M.; Christianson, D. W. Variable Active Site Loop Conformations Accommodate the Binding of Macrocyclic Largazole Analogues to HDAC8 Biochemistry 2015, 54, 2126-2135 10.1021/acs.biochem.5b00010
94. Yu, M.; Salvador, L. A.; Sy, S. K.; Tang, Y.; Singh, R. S.; Chen, Q. Y.; Liu, Y.; Hong, J.; Derendorf, H.; Luesch, H. Largazole Pharmacokinetics In Rats By LC-MS/MS Mar. Drugs 2014, 12, 1623-1640 10.3390/md12031623
95. Salvador, L. A.; Park, H.; Al-Awadhi, F. H.; Liu, Y.; Kim, B.; Zeller, S. L.; Chen, Q. Y.; Hong, J.; Luesch, H. Modulation Of Activity Profiles For Largazole-Based Hdac Inhibitors Through Alteration Of Prodrug Properties ACS Med. Chem. Lett. 2014, 5, 905-910 10.1021/ml500170r
96. Monk, P. N.; Scola, A.-M.; Madala, P. K.; Fairlie, D. P. Function, Structure And Therapeutic Potential Of Complement C5a Receptors Br. J. Pharmacol. 2007, 152, 429-448 10.1038/sj.bjp.0707332
97. Wong, A. K.; Finch, A. M.; Pierens, G. K.; Craik, D. J.; Taylor, S. M.; Fairlie, D. P. Small Molecular Probes For G-Protein-Coupled C5a Receptors: Conformationally Constrained Antagonists Derived From The C-Terminus Of The Human Plasma Protein C5a J. Med. Chem. 1998, 41, 3417-3425 10.1021/jm9800651
98. Finch, A. M.; Wong, A. K.; Wadi, S. K.; Paczkowski, N. J.; Fairlie, D. P.; Taylor, S. M. Low Molecular Weight Peptidic And Cyclic Antagonists Of The Receptor For The Complement Factor C5a J. Med. Chem. 1999, 42, 1965-1974 10.1021/jm9806594
99. March, D. R.; Proctor, L. M.; Stoermer, M. J.; Sbaglia, R.; Abbenante, G.; Reid, R. C.; Wadi, K.; Paczkowski, N.; Tyndall, J. D. A.; Taylor, S. M.; Fairlie, D. P. Potent Cyclic Antagonists Of The Complement C5a Receptor On Human Polymorphonuclear Leukocytes. Relationships Between Structures And Activity Mol. Pharmacol. 2004, 65, 868-879 10.1124/mol.65.4.868
100. Seow, V.; Lim, J.; Cotterell, A. J.; Yau, M. K.; Xu, W.; Lohman, R. J.; Kok, W. M.; Stoermer, M. J.; Sweet, M. J.; Reid, R. C. et al. Receptor Residence Time Trumps Drug-Likeness And Oral Bioavailability In Determining Efficacy Of Complement C5a Antagonists Sci. Rep. 2016, 6, 24575 10.1038/srep24575
101. Waksman, S. A.; Woodruff, H. B. Bacteriostatic And Bactericidal Substances Produced By A Soil Actinomyces Exp. Biol. Med. 1940, 45, 609-614 10.3181/00379727-45-11768
102. Jain, S. C.; Sobell, H. M. Stereochemistry Of Actinomycin Binding To DNA. I. Refinement And Further Structural Details Of The Actinomycin-Deoxyguanosine Crystalline Complex J. Mol. Biol. 1972, 68, 1-20
103. Lo, Y. S.; Tseng, W. H.; Chuang, C. Y.; Hou, M. H. The Structural Basis Of Actinomycin D-Binding Induces Nucleotide Flipping Out, A Sharp Bend And A Left-Handed Twist In CGG Triplet Repeats Nucleic Acids Res. 2013, 41, 4284-4294 10.1093/nar/gkt084
104. Robinson, H.; Gao, Y. G.; Yang, X.; Sanishvili, R.; Joachimiak, A.; Wang, A. H. Crystallographic Analysis Of A Novel Complex Of Actinomycin D Bound To The DNA Decamer CGATCGATCG Biochemistry 2001, 40, 5587-92 10.1021/bi002859z
105. Tan, C. T.; Dargeon, H. W.; Burchenal, J. H. The Effect Of Actinomycin D On Cancer In Childhood Pediatrics 1959, 24, 544-561
106. Hill, T. A.; Lohman, R. J.; Hoang, H. N.; Nielsen, D. S.; Scully, C. C.; Kok, W. M.; Liu, L.; Lucke, A. J.; Stoermer, M. J.; Schroeder, C. I. et al. Cyclic Penta- And Hexa-Leucine Peptides Without N-Methylation Are Orally Absorbed ACS Med. Chem. Lett. 2014, 5, 1148-1151 10.1021/ml5002823
107. Robson, W. L. M.; Leung, A. K. C.; Norgaard, J. P. The Comparative Safety Of Oral Versus Intranasal Desmopressin For The Treatment Of Children With Nocturnal Enuresis J. Urol. 2007, 178, 24-30 10.1016/j.juro.2007.03.015
108. Rembratt, A.; Graugaard-Jensen, C.; Senderovitz, T.; Norgaard, J. P.; Djurhuus, J. C. Pharmacokinetics And Pharmacodynamics Of Desmopressin Administered Orally Versus Intravenously At Daytime Versus Night-Time In Healthy Men Aged 55-70 Years Eur. J. Clin. Pharmacol. 2004, 60, 397-402 10.1007/s00228-004-0781-9
109. Fjellestad-Paulsen, A.; Hoglund, P.; Lundin, S.; Paulsen, O. Pharmacokinetics Of 1-Deamino-8-D-Arginine Vasopressin After Various Routes Of Administration In Healthy Volunteers Clin. Endocrinol. 1993, 38, 177-182 10.1111/j.1365-2265.1993.tb00990.x
110. D'agay-Abensour, L.; Fjellestad-Paulsen, A.; Höglund, P.; Ngô, Y.; Paulsen, O.; Rambaud, J. C. Absolute Bioavailability Of An Aqueous Solution Of 1-Deamino-8-D-Arginine Vasopressin From Different Regions Of The Gastrointestinal Tract In Man Eur. J. Clin. Pharmacol. 1993, 44, 473-476 10.1007/BF00315546
111. Lan, E.-L.; Ugwu, S. O.; Blanchard, J.; Fang, X.; Hruby, V. J.; Sharma, S. Preformulation Studies With Melanotan-II: A Potential Skin Cancer Chemopreventive Peptide J. Pharm. Sci. 1994, 83, 1081-1084 10.1002/jps.2600830805
112. Meyer-Lindenberg, A.; Domes, G.; Kirsch, P.; Heinrichs, M. Oxytocin And Vasopressin In The Human Brain: Social Neuropeptides For Translational Medicine Nat. Rev. Neurosci. 2011, 12, 524-538 10.1038/nrn3044
113. Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G. Oxytocin And Vasopressin Agonists And Antagonists As Research Tools And Potential Therapeutics J. Neuroendocrinol. 2012, 24, 609-628 10.1111/j.1365-2826.2012.02303.x
114. de Araujo, A. D.; Mobli, M.; Castro, J.; Harrington, A. M.; Vetter, I.; Dekan, Z.; Muttenthaler, M.; Wan, J.; Lewis, R. J.; King, G. F.; Brierley, S. M.; Alewood, P. F. Selenoether Oxytocin Analogues Have Analgesic Properties In A Mouse Model Of Chronic Abdominal Pain Nat. Commun. 2014, 5, 3165 10.1038/ncomms4165
115. Wood, S. P.; Tickle, I. J.; Treharne, A. M.; Pitts, J. E.; Mascarenhas, Y.; Li, J. Y.; Husain, J.; Cooper, S.; Blundell, T. L.; Hruby, V. J. et al. Crystal Structure Of Deamino-Oxytocin: Conformational Flexibility And Receptor Binding Science 1986, 232, 633-636 10.1126/science.3008332
116. Goetz, G. H.; Philippe, L.; Shapiro, M. J. Epsa: A Novel Supercritical Fluid Chromatography Technique Enabling The Design Of Permeable Cyclic Peptides ACS Med. Chem. Lett. 2014, 5, 1167-1172 10.1021/ml500239m
117. Zornes, L. L.; Stratford, R. E. Development Of A Plasma High-Performance Liquid Chromatographic Assay For LY303366, A Lipopeptide Antifungal Agent, And Its Application In A Dog Pharmacokinetic Study J. Chromatogr., Biomed. Appl. 1997, 695, 381-387 10.1016/S0378-4347(97)00184-9
118. Li, C.; Fleisher, D.; Li, L.; Schwier, J. R.; Sweetana, S. A.; Vasudevan, V.; Zornes, L. L.; Pao, L. H.; Zhou, S. Y.; Stratford, R. E. Regional-Dependent Intestinal Absorption And Meal Composition Effects On Systemic Availability Of LY303366, A Lipopeptide Antifungal Agent, In Dogs J. Pharm. Sci. 2001, 90, 47-57 10.1002/1520-6017(200101)90:1<47::AID-JPS6>3.0.CO;2-2
119. Raasch, R. H. Anidulafungin: Review Of A New Echinocandin Antifungal Agent Expert Rev. Anti-Infect. Ther. 2004, 2, 499-508 10.1586/14787210.2.4.499
120. Denning, D. W. Echinocandin Antifungal Drugs Lancet 2003, 362, 1142 10.1016/S0140-6736(03)14472-8
121. Ikeda, F.; Tanaka, S.; Ohki, H.; Matsumoto, S.; Maki, K.; Katashima, M.; Barrett, D.; Aoki, Y. Role Of Micafungin In The Antifungal Armamentarium Curr. Med. Chem. 2007, 14, 1263-1275 10.2174/092986707780597970
122. Morris, M. I.; Villmann, M. Echinocandins In The Management Of Invasive Fungal Infections, Part 1 Am. J. Health-Syst. Pharm. 2006, 63, 1693-1703 10.2146/ajhp050464.p1
123. Veber, D. F.; Holly, F. W.; Nutt, R. F.; Bergstrand, S. J.; Brady, S. F.; Hisrschmann, R.; Glitzer, M. S.; Saperstein, R. Highly Active Cyclic And Bicyclic Somatostatin Analogues Of Reduced Ring Size Nature 1979, 280, 512-514 10.1038/280512a0
124. Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Paleveda, W. J.; Holly, F. W.; Strachan, R. G.; Nutt, R. F.; Arison, B. H.; Homnick, C.; Randall, W. C. et al. A Potent Cyclic Hexapeptide Analogue Of Somatostatin Nature 1981, 292, 55-58 10.1038/292055a0
125. Biron, E.; Chatterjee, J.; Ovadia, O.; Langenegger, D.; Brueggen, J.; Hoyer, D.; Schmid, H. A.; Jelinek, R.; Gilon, C.; Hoffman, A. et al. Improving Oral Bioavailability Of Peptides By Multiple N-Methylation: Somatostatin Analogues Angew. Chem., Int. Ed. 2008, 47, 2595-2599 10.1002/anie.200705797
126. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T. J.; Pless, J. SMS 201-995: A Very Potent And Selective Octapeptide Analogue Of Somatostatin With Prolonged Action Life Sci. 1982, 31, 1133-1140 10.1016/0024-3205(82)90087-X
127. Melacini, G.; Zhu, Q.; Goodman, M. Multiconformational NMR Analysis Of Sandostatin (Octreotide): Equilibrium Between Beta-Sheet And Partially Helical Structures Biochemistry 1997, 36, 1233-1241 10.1021/bi962497o
128. Spyroulias, G. A.; Galanis, A. S.; Petrou, C. H.; Vahliotis, D.; Sotiriou, P.; Nikolopoulou, A.; Nock, B.; Maina, T.; Cordopatis, P. 3D Solution Structure Of [Tyr3]Octreotate Derivatives In DMSO: Structure Differentiation Of Peptide Core Due To Chelate Group Attachment And Biologically Active Conformation Med. Chem. 2005, 1, 487-499 10.2174/1573406054864089
129. Pohl, E.; Heine, A.; Sheldrick, G. M.; Dauter, Z.; Wilson, K. S.; Kallen, J.; Huber, W.; Pfaffli, P. J. Structure of Octreotide, a Somatostatin Analogue Acta Crystallogr., Sect. D: Biol. Crystallogr. 1995, 51, 48-59 10.1107/S0907444994006104
130. Köhler, E.; Duberow-Drewe, M.; Drewe, J.; Ribes, G.; Loubatières-Mariani, M. M.; Mazer, N.; Gyr, K.; Beglinger, C. Absorption Of An Aqueous Solution Of A New Synthetic Somatostatin Analogue Administered To Man By Gavage Eur. J. Clin. Pharmacol. 1987, 33, 167-171 10.1007/BF00544562
131. Williams, G.; Burrin, J. M.; Ball, J. A.; Joplin, G. F.; Bloom, S. R. Effective And Lasting Growth-Hormone Suppression In Active Acromegaly With Oral Administration Of Somatostatin Analogue SMS 201-995 Lancet 1986, 328, 774-778 10.1016/S0140-6736(86)90300-4
132. Albert, R.; Marbach, P.; Bauer, W.; Briner, U.; Fricker, G.; Brums, C.; Pless, J. SDZ CO 611: A Highly Potent Glycated Analog Of Somatostatin With Improved Oral Activity Life Sci. 1993, 53, 517-525 10.1016/0024-3205(93)90703-6
133. Nelson-Piercy, C.; Hammond, P. J.; Gwilliam, M. E.; Khandan-Nia, N.; Myers, M. J.; Ghatei, M. A.; Bloom, S. R. Effect Of A New Oral Somatostatin Analog (SDZ CO 611) On Gastric Emptying, Mouth To Cecum Transit Time, And Pancreatic And Gut Hormone Release In Normal Male Subjects J. Clin. Endocrinol. Metab. 1994, 78, 329-336 10.1210/jcem.78.2.7906279
134. Geddes, A. J.; Akrigg, D. The Crystal Structure of Hydrated Beauvericin Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem. 1976, 32, 3164-3171 10.1107/S0567740876009874
135. Braden, B.; Hamilton, J. A.; Sabesan, M. N.; Steinrauf, L. K. Crystal Structure Of A Beauvericin-Barium Picrate Complex J. Am. Chem. Soc. 1980, 102, 2704-2709 10.1021/ja00528a031
136. Plattner, R. D.; Nelson, P. E. Production Of Beauvericin By A Strain Of Fusarium Proliferatum Isolated From Corn Fodder For Swine Appl. Environ. Microbiol. 1994, 60, 3894-3896
137. Mei, L.; Zhang, L.; Dai, R. An Inhibition Study Of Beauvericin On Human And Rat Cytochrome P450 Enzymes And Its Pharmacokinetics In Rats J. Enzyme Inhib. Med. Chem. 2009, 24, 753-762 10.1080/14756360802362041
138. Streit, E.; Schwab, C.; Sulyok, M.; Naehrer, K.; Krska, R.; Schatzmayr, G. Multi-Mycotoxin Screening Reveals The Occurrence Of 139 Different Secondary Metabolites In Feed And Feed Ingredients Toxins 2013, 5, 504-523 10.3390/toxins5030504
139. Jestoi, M. Emerging Fusarium-Mycotoxins Fusaproliferin, Beauvericin, Enniatins, And Moniliformin: A Review Crit. Rev. Food Sci. Nutr. 2008, 48, 21-49 10.1080/10408390601062021
140. Ovchinnikov, Y. A.; Ivanov, V. T.; Evstratov, A. V.; Mikhaleva, I. I.; Bystrov, V. F.; Portnova, S. L.; Balashova, T. A.; Meshcheryakova, E. N.; Tulchinsky, V. M. The Enniatin Ionophores. Conformation And Ion Binding Properties Int. J. Pept. Protein Res. 1974, 6, 465-498 10.1111/j.1399-3011.1974.tb02407.x
141. Kratky, C.; Dobler, M. The Crystal Structure of Enniatin B Helv. Chim. Acta 1985, 68, 1798-1803 10.1002/hlca.19850680634
142. Tishchenko, G. N.; Zhukhlistova, N. E. Crystal and Molecular Structure of the Membrane-Active Antibiotic Enniatin C Crystallogr. Rep. 2000, 45, 677-683 10.1134/1.1306573
143. Tishchenko, G. N.; Karimov, Z. Structure Of Rubidium(1+) Complex Of The LDLLDL Analog Of Enniatin B In Crystals Kristallografiya (Russ.) Crystallogr.Rep. 1978, 23, 729-742
144. Zhukhlistova, N. E.; Tishchenko, G. N.; Refaat, L.; Woolfson, M. M. Crystal And Molecular Structure Of (Enniatin B)2.KI Complex Kristallografiya (Russ.) Crystallogr. Rep. 1998, 43, 50-57
145. Fæste, C. K.; Ivanova, L.; Uhlig, S. In Vitro Metabolism Of The Mycotoxin Enniatin B In Different Species And Cytochrome P450 Enzyme Phenotyping By Chemical Inhibitors Drug Metab. Dispos. 2011, 39, 1768-1776 10.1124/dmd.111.039529
146. Devreese, M.; Broekaert, N.; De Mil, T.; Fraeyman, S.; De Backer, P.; Croubels, S. Pilot Toxicokinetic Study And Absolute Oral Bioavailability Of The Fusarium Mycotoxin Enniatin B1 In Pigs Food Chem. Toxicol. 2014, 63, 161-165 10.1016/j.fct.2013.11.005
147. Lecci, A.; Carini, F.; Tramontana, M.; D'aranno, V.; Marinoni, E.; Crea, A.; Bueno, L.; Fioramonti, J.; Criscuoli, M.; Giuliani, S. et al. Nepadutant Pharmacokinetics And Dose-Effect Relationships As Tachykinin NK2 Receptor Antagonist Are Altered By Intestinal Inflammation In Rodent Models J. Pharmacol. Exp. Ther. 2001, 299, 247-254
148. https://clinicaltrials.gov/ct2/show/NCT00655083.
149. Jolad, S. D.; Hoffman, J. J.; Torrance, S. J.; Wiedhopf, R. M.; Cole, J. R.; Arora, S. K.; Bates, R. B.; Gargiulo, R. L.; Kriek, G. R. Bouvardin and Deoxybouvardin, Antitumor Cyclic Hexapeptides from Bouvardia ternifolia (Rubiaceae) J. Am. Chem. Soc. 1977, 99, 8040-8044 10.1021/ja00466a043
150. US NIH Toxnet, Substance Name: Bouvardin, 5-(N-methyl-L-tyrosine)-, acetate (ester). https://chem.nlm.nih.gov/chemidplus/rn/86229-75-6.
151. Reid, A. B.; Daffy, J. R.; Stanley, P.; Buising, K. L. Use Of Pristinamycin For Infections By Gram-Positive Bacteria: Clinical Experience At An Australian Hospital Antimicrob. Agents Chemother. 2010, 54, 3949-3952 10.1128/AAC.00212-10
152. Andes, D.; Craig, W. A. Pharmacodynamics Of A New Streptogramin, XRP 2868, In Murine Thigh And Lung Infection Models Antimicrob. Agents Chemother. 2006, 50, 243-249 10.1128/AAC.50.1.243-249.2006
153. Rezai, T.; Yu, B.; Millhauser, G. L.; Jacobson, M. P.; Lokey, R. S. Testing The Conformational Hypothesis Of Passive Membrane Permeability Using Synthetic Cyclic Peptide Diastereomers J. Am. Chem. Soc. 2006, 128, 2510-2511 10.1021/ja0563455
154. Rezai, T.; Bock, J. E.; Zhou, M. V.; Kalyanaraman, C.; Lokey, R. S.; Jacobson, M. P. Conformational Flexibility, Internal Hydrogen Bonding, And Passive Membrane Permeability: Successful In Silico Prediction Of The Relative Permeabilities Of Cyclic Peptides J. Am. Chem. Soc. 2006, 128, 14073-14080 10.1021/ja063076p
155. White, T. R.; Renzelman, C. M.; Rand, A. C.; Rezai, T.; Mcewen, C. M.; Gelev, V. M.; Turner, R. A.; Linington, R. G.; Leung, S. S. F.; Kalgutkar, A. S. et al. On-Resin N-Methylation Of Cyclic Peptides For Discovery Of Orally Bioavailable Scaffolds Nat. Chem. Biol. 2011, 7, 810-817 10.1038/nchembio.664
156. Rand, A. C.; Leung, S. S.; Eng, H.; Rotter, C. J.; Sharma, R.; Kalgutkar, A. S.; Zhang, Y.; Varma, M. V.; Farley, K. A.; Khunte, B. et al. Optimizing PK Properties Of Cyclic Peptides: The Effect Of Side Chain Substitutions On Permeability And Clearance MedChemComm 2012, 3, 1282-1289 10.1039/c2md20203d
157. Schwochert, J.; Turner, R.; Thang, M.; Berkeley, R. F.; Ponkey, A. R.; Rodriguez, K. M.; Leung, S. S.; Khunte, B.; Goetz, G. Limberakis, C. et al. Peptide To Peptoid Substitutions Increase Cell Permeability In Cyclic Hexapeptides Org. Lett. 2015, 17, 2928-2931 10.1021/acs.orglett.5b01162
158. Bockus, A. T.; Lexa, K. W.; Pye, C. R.; Kalgutkar, A. S.; Gardner, J. W.; Hund, K. C.; Hewitt, W. M.; Schwochert, J. A.; Glassey, E.; Price, D. A. et al. Probing The Physicochemical Boundaries Of Cell Permeability And Oral Bioavailability In Lipophilic Macrocycles Inspired By Natural Products J. Med. Chem. 2015, 58, 4581-4589 10.1021/acs.jmedchem.5b00128
159. Lewis, I.; Schaefer, M.; Wagner, T.; Oberer, L.; Sager, E.; Wipfli, P.; Vorherr, T. A Detailed Investigation On Conformation, Permeability And PK Properties Of Two Related Cyclohexapeptides Int. J. Pept. Res. Ther. 2015, 21, 205-221 10.1007/s10989-014-9447-3
160. Wang, C. K.; Northfield, S. E.; Colless, B.; Chaousis, S.; Hamernig, I.; Lohman, R. J.; Nielsen, D. S.; Schroeder, C. I.; Liras, S.; Price, D. A. et al. Rational Design And Synthesis Of An Orally Bioavailable Peptide Guided By NMR Amide Temperature Coefficients Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 17504-17509 10.1073/pnas.1417611111
161. Nielsen, D. S.; Lohman, R. J.; Hoang, H. N.; Hill, T. A.; Jones, A.; Lucke, A. J.; Fairlie, D. P. Flexibility Versus Rigidity For Orally Bioavailable Cyclic Hexapeptides ChemBioChem 2015, 16, 2289-2293 10.1002/cbic.201500441
162. Bechara, C.; Sagan, S. Cell-Penetrating Peptides: 20 Years Later, Where Do We Stand? FEBS Lett. 2013, 587, 1693-1702 10.1016/j.febslet.2013.04.031
163. Kauffman, W. B.; Fuselier, T.; He, J.; Wimley, W. C. Mechanism Matters: A Taxonomy Of Cell Penetrating Peptides Trends Biochem. Sci. 2015, 40, 749-764 10.1016/j.tibs.2015.10.004
164. Tashima, T. Intelligent Substance Delivery Into Cells Using Cell-Penetrating Peptides Bioorg. Med. Chem. Lett. 2017, 27, 121-130 10.1016/j.bmcl.2016.11.083
165. Qian, Z.; Martyna, A.; Hard, R. L.; Wang, J.; Appiah-Kubi, G.; Coss, C.; Phelps, M. A.; Rossman, J. S.; Pei, D. Discovery And Mechanism Of Highly Efficient Cyclic Cell-Penetrating Peptides Biochemistry 2016, 55, 2601-2612 10.1021/acs.biochem.6b00226
166. Hamann, M. T.; Scheuer, P. J. Kahalalide-F-A Bioactive Depsipeptide From The Sacoglossan Mollusk Elysia-Rufescens And The Green-Alga Bryopsis Sp J. Am. Chem. Soc. 1993, 115, 5825-5826 10.1021/ja00066a061
167. Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Munoz, A.; Kahalalide, F. A New Marine-Derived Compound, Induces Oncosis In Human Prostate And Breast Cancer Cells Mol. Cancer Ther. 2003, 2, 863-872
168. Rademaker-Lakhai, J. M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; De Reijke, T. M.; Jimeno, J. M.; Lopez-Lazaro, L.; Lopez Martin, J. A.; Beijnen, J. H.; Schellens, J. H. Phase I Clinical And Pharmacokinetic Study Of Kahalalide F In Patients With Advanced Androgen Refractory Prostate Cancer Clin. Cancer Res. 2005, 11, 1854-1862 10.1158/1078-0432.CCR-04-1534
169. Brown, A. P.; Morrissey, R. L.; Faircloth, G. T.; Levine, B. S. Preclinical Toxicity Studies Of Kahalalide F, A New Anticancer Agent: Single And Multiple Dosing Regimens In The Rat Cancer Chemother. Pharmacol. 2002, 50, 333-340 10.1007/s00280-002-0499-2
170. Dalisay, D. S.; Rogers, E. W.; Edison, A. S.; Molinski, T. F. Structure Elucidation At The Nanomole Scale. 1. Trisoxazole Macrolides And Thiazole-Containing Cyclic Peptides From The Nudibranch Hexabranchus Sanguineus J. Nat. Prod. 2009, 72, 732-738 10.1021/np8007649
171. Nielsen, D. S.; Hoang, H. N.; Lohman, R. J.; Diness, F.; Fairlie, D. P. Total Synthesis, Structure, And Oral Absorption Of A Thiazole Cyclic Peptide, Sanguinamide A Org. Lett. 2012, 14, 5720-5723 10.1021/ol3027347
172. Nielsen, D. S.; Hoang, H. N.; Lohman, R. J.; Hill, T. A.; Lucke, A. J.; Craik, D. J.; Edmonds, D. J.; Griffith, D. A.; Rotter, C. J.; Ruggeri, R. B. et al. Improving On Nature: Making A Cyclic Heptapeptide Orally Bioavailable Angew. Chem., Int. Ed. 2014, 53, 12059-12063 10.1002/anie.201405364
173. Steyn, P. S.; Tuinman, A. A.; Van Heerden, F. R.; Van Rooyen, P. H.; Wessels, P. L.; Rabie, C. J. The Isolation, Structure, And Absolute Configuration Of The Mycotoxin, Rhizonin A, A Novel Cyclic Heptapeptide Containing N-Methyl-3-(3-Furyl)Alanine, Produced By Rhizopus Microsporus J. Chem. Soc., Chem. Commun. 1983, 47-49 10.1039/c39830000047
174. Wilson, T.; Rabie, C. J.; Fincham, J. E.; Steyn, P. S.; Schipper, M. A. Toxicity Of Rhizonin A, Isolated From Rhizopus Microsporus, In Laboratory Animals Food Chem. Toxicol. 1984, 22, 275-281 10.1016/0278-6915(84)90006-1
175. Ernst, B.; Hoeger, S. J.; O'brien, E.; Dietrich, D. R. Oral Toxicity Of The Microcystin-Containing Cyanobacterium Planktothrix Rubescens In European Whitefish (Coregonus Lavaretus) Aquat. Toxicol. 2006, 79, 31-40 10.1016/j.aquatox.2006.04.013
176. Yoshida, T.; Makita, Y.; Nagata, S.; Tsutsumi, T.; Yoshida, F.; Sekijima, M.; Tamura, S.; Ueno, Y. Acute Oral Toxicity Of Microcystin-LR, A Cyanobacterial Hepatotoxin, In Mice Nat. Toxins 1997, 5, 91-95 10.1002/nt.1
177. Ito, E.; Kondo, F.; Harada, K. First Report On The Distribution Of Orally Administered Microcystin-LR In Mouse Tissue Using An Immunostaining Method Toxicon 2000, 38, 37-48 10.1016/S0041-0101(99)00084-7
178. Kawasaki, T.; Taniguchi, M.; Moritani, Y.; Uemura, T.; Shigenaga, T.; Takamatsu, H.; Hayashi, K.; Takasaki, J.; Saito, T.; Nagai, K. Pharmacological Properties Of YM-254890, A Specific G(Alpha)q/11 Inhibitor, On Thrombosis And Neointima Formation In Mice Thromb. Haemostasis 2005, 94, 184-192 10.1160/TH04-09-0635
179. 2 Inhibition By CHEC Sequences Including Oral Treatment Of Experimental Autoimmune Myeloencephalitis Open Enzyme Inhib. J. 2009, 2, 1-7 10.2174/1874940200902010001
180. Kicielinska, J.; Szczygiel, A.; Rossowska, J.; Anger, N.; Kempinska, K.; Switalska, M.; Kaszowska, M.; Wietrzyk, J.; Boratynski, J.; Pajtasz-Piasecka, E. Oral Administration Of Polymyxin B Modulates The Activity Of Lipooligosaccharide E. Coli B Against Lung Metastases In Murine Tumor Models PLoS One 2016, 11, E0148156 10.1371/journal.pone.0148156
181. Adachi, Y.; Enomoto, M.; Adachi, M.; Suwa, M.; Nagamine, Y.; Nanno, T.; Hashimoto, T.; Inoue, H.; Yamamoto, T. Enteric Coated Polymyxin B In The Treatment Of Hyperammonemia And Endotoxemia In Liver Cirrhosis Gastroenterol. Jpn. 1982, 17, 550-557
182. Dudley, M. N.; Mclaughlin, J. C.; Carrington, G.; Frick, J. Nightingale, C. H.; Quintiliani, R. Oral Bacitracin Vs Vancomycin Therapy For Clostridium Difficile-Induced Diarrhea. A Randomized Double-Blind Trial Arch. Intern. Med. 1986, 146, 1101-1104 10.1001/archinte.146.6.1101
183. Bond, G. C.; Vanderbrook, M. J.; Wiley, J. L.; Nook, M. A. Oral Administration Of Bacitracin Exp. Biol. Med. 1948, 68, 395-400 10.3181/00379727-68-16496
184. Weinstein, M. R.; Dedier, H.; Brunton, J.; Campbell, I.; Conly, J. M. Lack Of Efficacy Of Oral Bacitracin Plus Doxycycline For The Eradication Of Stool Colonization With Vancomycin-Resistant Enterococcus Faecium Clin. Infect. Dis. 1999, 29, 361-366 10.1086/520216
185. https://www.drugbank.ca/drugs/DB00626.
186. Sasaki, T.; Takagi, M.; Yaguchi, T.; Miyadoh, S.; Okada, T.; Koyama, M. A New Anthelmintic Cyclodepsipeptide, PF1022a J. Antibiot. 1992, 45, 692-697 10.7164/antibiotics.45.692
187. Kachi, S.; Ishih, A.; Terada, M. Effects Of Pf1022a On Adult Angiostrongylus Cantonensis In The Pulmonary Arteries And Larvae Migrating Into The Central Nervous System Of Rats Z. Parasitenkd. 1995, 81, 631-637 10.1007/BF00931838
188. Von Samson-Himmelstjerna, G.; Harder, A.; Sangster, N. C.; Coles, G. C. Efficacy Of Two Cyclooctadepsipeptides, Pf1022a And Emodepside, Against Anthelmintic-Resistant Nematodes In Sheep And Cattle Parasitology 1999, 130, 343-347 10.1017/S0031182004006523
189. Harder, A.; Holden-Dye, L.; Walker, R.; Wunderlich, F. Mechanisms Of Action Of Emodepside Parasitol. Res. 2005, 97, S1-S10 10.1007/s00436-005-1438-z
190. Harder, A.; Schmitt-Wrede, H.-P.; Krucken, J.; Marinovski, P.; Wunderlich, F.; Willson, J.; Amliwala, K.; Holden-Dye, L.; Walker, R. Cyclooctadepsipeptides-An Anthelmintically Active Class Of Compounds Exhibiting A Novel Mode Of Action Int. J. Antimicrob. Agents 2003, 22, 318-331 10.1016/S0924-8579(03)00219-X
191. Ohyama, M.; Okada, Y.; Takahashi, M.; Sakanaka, O.; Matsumoto, M.; Atsumi, K. Structure-Activity Relationship Of Anthelmintic Cyclooctadepsipeptides Biosci., Biotechnol., Biochem. 2011, 75, 1354-1363 10.1271/bbb.110129
192. Baronsky, J.; Bongaerts, S.; Traeubel, M.; Weiss, H.-C.; Urbanetz, N. The Study Of Different Solid Forms Of Emodepside Eur. J. Pharm. Biopharm. 2009, 71, 88-99 10.1016/j.ejpb.2008.06.003
193. https://clinicaltrials.gov/ct2/show/NCT02661178.
194. Gao, Z. Q.; Zhao, X. Y.; Lee, S.; Li, J. J.; Liao, H.; Zhou, X. H.; Wu, J.; Qi, G. F. WH1fungin A Surfactin Cyclic Lipopeptide Is A Novel Oral Immunoadjuvant Vaccine 2013, 31, 2796-2803 10.1016/j.vaccine.2013.04.028
195. Gao, Z. Q.; Zhao, X. Y.; Yang, T.; Shang, J.; Shang, L.; Mai, H. Z.; Qi, G. F. Immunomodulation Therapy Of Diabetes By Oral Administration Of A Surfactin Lipopeptide In NOD Mice Vaccine 2014, 32, 6812-6819 10.1016/j.vaccine.2014.08.082
196. Wieland, T.; Faulstich, H. Amatoxins, Phallotoxins, Phallolysin, And Antamanide: The Biologically Active Components Of Poisonous Amanita Mushrooms Crit. Rev. Biochem. 1978, 5, 185-260 10.3109/10409237809149870
197. Faulstich, H.; Buku, A.; Bodenmuller, H.; Wieland, T. Virotoxins: Actin-Binding Cyclic Peptides Of Amanita Virosa Mushrooms Biochemistry 1980, 19, 3334-3343 10.1021/bi00555a036
198. Wong, J. H.; Ng, T. B. In Handbook Of Biologically Active Peptides; Abba, J. K., Ed.; Academic Press: New York, 2006; pp 131-135.
199. Walton, J. D.; Hallen-Adams, H. E.; Luo, H. Ribosomal Biosynthesis Of The Cyclic Peptide Toxins Of Amanita Mushrooms Biopolymers 2010, 94, 659-664 10.1002/bip.21416
200. Bushnell, D. A.; Cramer, P.; Kornberg, R. D. Structural Basis of Transcription: Alpha-Amanitin-RNA Polymerase II Cocrystal at 2.8 Å Resolution Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 1218-122 10.1073/pnas.251664698
201. Brueckner, F.; Cramer, P. Structural Basis of Transcription Inhibition by Alpha-Amanitin and Implications for RNA Polymerase II Translocation Nat. Struct. Mol. Biol. 2008, 15, 811-818 10.1038/nsmb.1458
202. Kaplan, C. D.; Larsson, K. M.; Kornberg, R. D. The RNA Polymerase II Trigger Loop Functions in Substrate Selection and is Directly Targeted by Alpha-Amanitin Mol. Cell 2008, 30, 547-556 10.1016/j.molcel.2008.04.023
203. Wieland, T.; Gotzendorfer, C.; Dabrowski, J.; Lipscomb, W. N.; Shoham, G. Unexpected Similarity of the Structures of the Weakly Toxic Amanitin (S)-Sulfoxide and the Highly Toxic (R)-Sulfoxide and Sulfone As Revealed by Proton Nuclear Magnetic Resonance and X-ray Analysis Biochemistry 1983, 22, 1264-1271 10.1021/bi00274a043
204. Shoham, G.; Lipscomb, W. N.; Wieland, T. Conformations of Amatoxins in the Crystalline State J. Am. Chem. Soc. 1989, 111, 4791-4809 10.1021/ja00195a036
205. Mas, A. Mushrooms, Amatoxins And The Liver J. Hepatol. 2005, 42, 166-169 10.1016/j.jhep.2004.12.003
206. Wieland, T. Peptides Of Poisonous Amanita Mushrooms; Springer-Verlag: Berlin, 1986.
207. Terlain, B.; Thomas, J. P. Structure Of Griselimycin, Polypeptide Antibiotic Extracted Streptomyces Cultures. I. Identification Of The Products Liberated By Hydrolysis Bull. Soc. Chim. Fr. 1971, 6, 2349-2356
208. Kling, A.; Lukat, P.; Almeida, D. V.; Bauer, A.; Fontaine, E.; Sordello, S.; Zaburannyi, N.; Herrmann, J.; Wenzel, S. C.; Konig, C. et al. Antibiotics. Targeting Dnan For Tuberculosis Therapy Using Novel Griselimycins Science 2015, 348, 1106-1112 10.1126/science.aaa4690
209. Holzgrabe, U. New Griselimycins For Treatment Of Tuberculosis Chem. Biol. 2015, 22, 981-982 10.1016/j.chembiol.2015.08.002
210. Nakajima, M.; Torikata, A.; Ichikawa, Y.; Katayama, T.; Shiraishi, A.; Haneishi, T.; Arai, M. Mycoplanecins, Novel Antimycobacterial Antibiotics From Actinoplanes Awajinensis Subsp. Mycoplanecinus Subsp. Nov. II. Isolation, Physico-Chemical Characterization And Biological Activities Of Mycoplanecin A J. Antibiot. 1983, 36, 961-966 10.7164/antibiotics.36.961
211. Haneishi, T.; Nakajima, M.; Shiraishi, A.; Katayama, T.; Torikata, A.; Kawahara, Y.; Kurihara, K.; Arai, M.; Arai, T.; Aoyagi, T. et al. Antimycobacterial Activities In Vitro And In Vivo And Pharmacokinetics Of Dihydromycoplanecin A Antimicrob. Agents Chemother. 1988, 32, 110-116 10.1128/AAC.32.1.110
212. Cunningham, T. J.; Greenstein, J. I.; Loewenstern, J.; Degermentzidis, E.; Yao, L. H. Anti-Inflammatory Peptide Regulates The Supply Of Heat Shock Protein 70 Monomers: Implications For Aging And Age-Related Disease Rejuvenation Res. 2015, 18, 136-144 10.1089/rej.2014.1620
213. Mesfin, F. B.; Bennett, J. A.; Jacobson, H. I.; Zhu, S.; Andersen, T. T. Alpha-Fetoprotein-Derived Antiestrotrophic Octapeptide Biochim. Biophys. Acta, Mol. Basis Dis. 2000, 1501, 33-43 10.1016/S0925-4439(00)00008-9
214. Defreest, L. A.; Mesfin, F. B.; Joseph, L.; Mcleod, D. J.; Stallmer, A.; Reddy, S.; Balulad, S. S.; Jacobson, H. I.; Andersen, T. T.; Bennett, J. A. Synthetic Peptide Derived From A-Fetoprotein Inhibits Growth Of Human Breast Cancer: Investigation Of The Pharmacophore And Synthesis Optimization J. Pept. Res. 2004, 63, 409-419 10.1111/j.1399-3011.2004.00139.x
215. Bennett, J. A.; Defreest, L.; Anaka, I.; Saadati, H.; Balulad, S.; Jacobson, H. I.; Andersen, T. T. Afpep: An Anti-Breast Cancer Peptide That Is Orally Active Breast Cancer Res. Treat. 2006, 98, 133-141 10.1007/s10549-005-9140-5
216. Mesfin, F. B.; Andersen, T. T.; Jacobson, H. I.; Zhu, S.; Bennett, J. A. Development Of A Synthetic Cyclized Peptide Derived From Alpha-Fetoprotein That Prevents The Growth Of Human Breast Cancer J. Pept. Res. 2001, 58, 246-256 10.1034/j.1399-3011.2001.00922.x
217. Fehrenbach, T.; Cui, Y.; Faulstich, H.; Keppler, D. Characterization Of The Transport Of The Bicyclic Peptide Phalloidin By Human Hepatic Transport Proteins Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 368, 415-420 10.1007/s00210-003-0814-4
218. Siemion, I. Z.; Pçdyczak, A.; Trojnar, J.; Zimecki, M.; Wieczorek, Z. Immunosuppressive Activity Of Antamanide And Some Of Its Analogues Peptides 1992, 13, 1233-1237 10.1016/0196-9781(92)90034-Z
219. 20 Proc. Natl. Acad. Sci. U. S. A. 1979, 76, 1532-1536 10.1073/pnas.76.4.1532
220. Di Blasio, B.; Rossi, F.; Benedetti, E.; Pavone, V.; Pedone, C.; Temussi, P. A.; Zanotti, G.; Tancredi, T. Bioactive Peptides: Solid-State And Solution Conformation Of Cyclolinopeptide A J. Am. Chem. Soc. 1989, 111, 9089-9098 10.1021/ja00207a015
221. Quail, J. W.; Shen, J.; Reaney, M. J. T.; Sammynaiken, R. Cyclolinopeptide A Methanol Solvate Acta Crystallogr., Sect. E: Struct. Rep. Online 2009, 65, 1913-1914 10.1107/S1600536809026841
222. Emmer, G.; Grassberger, M. A.; Meingassner, J. G.; Schulz, G.; Schaude, M. Derivatives Of A Novel Cyclopeptolide. 1. Synthesis, Antifungal Activity, And Structure-Activity Relationships J. Med. Chem. 1994, 37, 1908-1917 10.1021/jm00039a002
223. Takahara, Y.; Takeuchi, Y.; Komura, I.; Hirose, Y.; Murao, S. Isolation Of A New Peptide Antibiotic, Permetin A, From Bacillus Circulans J. Antibiot. 1979, 32, 115-120 10.7164/antibiotics.32.115
224. Fouche, M.; Schafer, M.; Berghausen, J.; Desrayaud, S.; Blatter, M.; Piechon, P.; Dix, I.; Martin Garcia, A.; Roth, H. J. Design And Development Of A Cyclic Decapeptide Scaffold With Suitable Properties For Bioavailability And Oral Exposure ChemMedChem 2016, 11, 1048-1059 10.1002/cmdc.201600082
225. Fouche, M.; Schafer, M.; Blatter, M.; Berghausen, J.; Desrayaud, S.; Roth, H. J. Pharmacokinetic Studies Around The Mono- And Difunctionalization Of A Bioavailable Cyclic Decapeptide Scaffold ChemMedChem 2016, 11, 1060-1068 10.1002/cmdc.201600083
226. Mascio, C. T.; Mortin, L. I.; Howland, K. T.; Van Praagh, A. D.; Zhang, S.; Arya, A.; Chuong, C. L.; Kang, C.; Li, T.; Silverman, J. A. In Vitro And In Vivo Characterization Of CB-183,315, A Novel Lipopeptide Antibiotic For Treatment Of Clostridium Difficile Antimicrob. Agents Chemother. 2012, 56, 5023-5030 10.1128/AAC.00057-12
227. Snydman, D. R.; Jacobus, N. V.; Mcdermott, L. A. Activity Of A Novel Cyclic Lipopeptide, CB-183,315 Against Resistant Clostridium Difficile And Other Gram Positive Aerobic And Anaerobic Intestinal Pathogens Antimicrob. Agents Chemother. 2012, 56, 3448-3452 10.1128/AAC.06257-11
228. Knight-Connoni, V.; Mascio, C.; Chesnel, L.; Silverman, J. Discovery And Development Of Surotomycin For The Treatment Of Clostridium Difficile J. Ind. Microbiol. Biotechnol. 2016, 43, 195-204 10.1007/s10295-015-1714-6
229. https://clinicaltrials.gov/ct2/show/NCT01597505.
230. Grevel, J.; Nuesch, E.; Abisch, E.; Kutz, K. Pharmacokinetics Of Oral Cyclosporin A (Sandimmun) In Healthy Subjects Eur. J. Clin. Pharmacol. 1986, 31, 211-216 10.1007/BF00606661
231. Jin, M.; Shimada, T.; Shintani, M.; Yokogawa, K.; Nomura, M.; Miyamoto, K. Long-Term Levothyroxine Treatment Decreases The Oral Bioavailability Of Cyclosporin A By Inducing P-Glycoprotein In Small Intestine Drug Metab. Pharmacokinet. 2005, 20, 324-330 10.2133/dmpk.20.324
232. Loosli, H.-R.; Kessler, H.; Oschkinat, H.; Weber, H.-P.; Petcher, T. J.; Widmer, A. Peptide Conformations. Part 31. The Conformation Of Cyclosporin A In The Crystal And In Solution Helv. Chim. Acta 1985, 68, 682-704 10.1002/hlca.19850680319
233. Pflügl, G.; Kallen, J.; Schirmer, T.; Jansonius, J. N.; Zurini, M. G.; Walkinshaw, M. D. X-Ray Structure Of A Decameric Cyclophilin-Cyclosporin Crystal Complex Nature 1993, 361, 91-94 10.1038/361091a0
234. Mikol, V.; Kallen, J.; Pflugl, G.; Walkinshaw, M. D. X-Ray Structure Of A Monomeric Cyclophilin A-Cyclosporin A Crystal Complex At 2.1Å Resolution J. Mol. Biol. 1993, 234, 1119-1130 10.1006/jmbi.1993.1664
235. Weber, C.; Wider, G.; Von Freyberg, B.; Traber, R.; Braun, W.; Widmer, H.; Wuthrich, K. The NMR Structure Of Cyclosporin A Bound To Cyclophilin In Aqueous Solution Biochemistry 1991, 30, 6563-6574 10.1021/bi00240a029
236. 13C]cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding Biochemistry 1991, 30, 6574-6583 10.1021/bi00240a030
237. Cho, H.; Chung, Y. Water Soluble Cyclosporine Monomethoxy Poly(Ethyleneglycol) Conjugates As Potential Prodrugs Arch. Pharmacal Res. 2004, 27, 662-669 10.1007/BF02980167
238. Rosenwirth, B.; Billich, A.; Datema, R.; Donatsch, P.; Hammerschmid, F.; Harrison, R.; Hiestand, P.; Jaksche, H.; Mayer, P.; Peichl, P. et al. Inhibition Of Human Immunodeficiency Virus Type 1 Replication By SNZ NIM 811, A Non-Immunosuppressive Cyclosporine Analog Antimicrob. Agents Chemother. 1994, 38, 1763-1772 10.1128/AAC.38.8.1763
239. Hopkins, S.; Scorneaux, B.; Huang, Z.; Murray, M. G.; Wring, S.; Smitley, C.; Harris, R.; Erdmann, F.; Fischer, G.; Ribeill, Y. SCY-635, A Novel Nonimmunosuppressive Analog Of Cyclosporine That Exhibits Potent Inhibition Of Hepatitis C Virus RNA Replication In Vitro Antimicrob. Agents Chemother. 2010, 54, 660-672 10.1128/AAC.00660-09
240. Ptak, R. G.; Gallay, P. A.; Jochmans, D.; Halestrap, A. P.; Ruegg, U. T.; Pallansch, L. A.; Bobardt, M. D.; De Béthune, M.-P.; Neyts, J.; De Clercq, E. et al. Inhibition Of Human Immunodeficiency Virus Type 1 Replication In Human Cells By DEBIO-025, A Novel Cyclophilin Binding Agent Antimicrob. Agents Chemother. 2008, 52, 1302-1317 10.1128/AAC.01324-07
241. Flisiak, R.; Horban, A.; Gallay, P.; Bobardt, M.; Selvarajah, S.; Wiercinska-Drapalo, A.; Siwak, E.; Cielniak, I.; Higersberger, J.; Kierkus, J. et al. The Cyclophilin Inhibitor DEBIO-025 Shows Potent Anti-Hepatitis C Effect In Patients Coinfected With Hepatitis C And Human Immunodeficiency Virus Hepatology 2008, 47, 817-826 10.1002/hep.22131
242. Gallay, P.; Lin, K. Profile Of Alisporivir And Its Potential In The Treatment Of Hepatitis C Drug Des., Dev. Ther. 2013, 7, 105-115 10.2147/DDDT.S30946
243. Sugimoto, H.; Lebleu, V. S.; Bosukonda, D.; Keck, P.; Taduri, G.; Bechtel, W.; Okada, H.; William, C.; Bey, P.; Rusckowski, M. et al. Activin-Like Kinase 3 Is Important For Kidney Regeneration And Reversal Of Fibrosis Nat. Med. 2012, 18, 396-404 10.1038/nm.2629
244. Rose, L.; Jenkins, A. T. A. The Effect Of The Ionophore Valinomycin On Biomimetic Solid Supported Lipid DPPTE/EPC Membranes Bioelectrochemistry 2007, 70, 387-393 10.1016/j.bioelechem.2006.05.009
245. Agata, N.; Ohta, M.; Mori, M.; Isobe, M. A Novel Dodecadepsipeptide, Cereulide, Is An Emetic Toxin Of Bacillus-Cereus FEMS Microbiol. Lett. 1995, 129, 17-19 10.1016/0378-1097(95)00119-P
246. Amr, A. E.-G. E.; Abo-Ghalia, M. H.; Abdalah, M. M. Synthesis Of New (N-A-Dipicolinoyl)-Bis-L-Valyl-L-Phenylalanyl Linear And Macrocyclic Bridged Peptides As Anti-Inflammatory Agents Arch. Pharm. 2007, 340, 304-309 10.1002/ardp.200600187
247. Busby, R. W.; Bryant, A. P.; Bartolini, W. P.; Cordero, E. A.; Hannig, G.; Kessler, M. M.; Mahajan-Miklos, S.; Pierce, C. M.; Solinga, R. M.; Sun, L. J. et al. Linaclotide, Through Activation Of Guanylate Cyclase C, Acts Locally In The Gastrointestinal Tract To Elicit Enhanced Intestinal Secretion And Transit Eur. J. Pharmacol. 2010, 649, 328-335 10.1016/j.ejphar.2010.09.019
248. Blanchfield, J. T.; Gallagher, O. P.; Cros, C.; Lewis, R. J.; Alewood, P. F.; Toth, I. Oral Absorption And In Vivo Biodistribution Of [Alpha]-Conotoxin MII And A Lipidic Analogue Biochem. Biophys. Res. Commun. 2007, 361, 97-102 10.1016/j.bbrc.2007.06.138
249. Clark, R. J.; Jensen, J.; Nevin, S. T.; Callaghan, B. P.; Adams, D. J.; Craik, D. J. The Engineering Of An Orally Active Conotoxin For The Treatment Of Neuropathic Pain Angew. Chem., Int. Ed. 2010, 49, 6545-6548 10.1002/anie.201000620
250. McNulty, M. J.; Hutabarat, R. H.; Findlay, J. W.; Devereux, K.; Knick, V. C.; Harvey, R. J.; Molina, L. Pharmacokinetics And Tissue Distribution Of The Nonadecapeptide MOLI-1901 In Rats And Mice Xenobiotica 2003, 33, 197-210 10.1080/0049825021000022320
251. Pinto, M. F. S.; Almeida, R. G.; Porto, W. F.; Fensterseifer, I. C. M.; Lima, L. A.; Dias, S. C.; Franco, O. L. Cyclotides: From Gene Structure To Promiscuous Multifunctionality J. Evidence-Based Complementary Altern. Med. 2012, 17, 40-53 10.1177/2156587211428077
252. Gran, L. On The Effect Of A Polypeptide Isolated From ″Kalata-Kalata″ (Oldenlandia Affinis DC) On The Oestrogen Dominated Uterus Acta Pharmacol. Toxicol. 1973, 33, 400-408 10.1111/j.1600-0773.1973.tb01541.x
253. Wong, C. T. T.; Rowlands, D. K.; Wong, C.-H.; Lo, T. W. C.; Nguyen, G. K. T.; Li, H.-Y.; Tam, J. P. Orally Active Peptidic Bradykinin B1 Receptor Antagonists Engineered From A Cyclotide Scaffold For Inflammatory Pain Treatment Angew. Chem., Int. Ed. 2012, 51, 5620-5624 10.1002/anie.201200984
254. Henriques, S. T.; Craik, D. J. Importance Of The Cell Membrane On The Mechanism Of Action Of Cyclotides ACS Chem. Biol. 2012, 7, 626-636 10.1021/cb200395f
255. Thell, K.; Hellinger, R.; Sahin, E.; Michenthaler, P.; Gold-Binder, M.; Haider, T.; Kuttke, M.; Liutkeviciute, Z.; Goransson, U.; Grundemann, C. et al. Oral Activity Of A Nature-Derived Cyclic Peptide For The Treatment Of Multiple Sclerosis Proc. Natl. Acad. Sci. U. S. A. 2016, 113, 3960-3965 10.1073/pnas.1519960113
256. QikProp, Schrödinger, LLC: New York, 2016; Schrödinger Release 2016-1.
257. Bird, G. H.; Madani, N.; Perry, A. F.; Princiotto, A. M.; Supko, J. G.; He, X.; Gavathiotis, E.; Sodroski, J. G.; Walensky, L. D. Hydrocarbon Double-Stapling Remedies The Proteolytic Instability Of A Lengthy Peptide Therapeutic Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 14093-14098 10.1073/pnas.1002713107
258. Mannhold, R. I.; Poda, G. I.; Ostermann, C.; Tetko, I. V. Calculation Of Molecular Lipophilicity: State-Of-The-Art And Comparison Of Log P Methods On More Than 96,000 Compounds J. Pharm. Sci. 2009, 98, 861-893 10.1002/jps.21494
259. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases J. Comb. Chem. 1999, 1, 55-68 10.1021/cc9800071
260. Stewart, W. E.; Siddall, T. H. Nuclear Magnetic Resonance Studies Of Amides Chem. Rev. 1970, 70, 517-551 10.1021/cr60267a001
261. Lu, J. J.; Crimin, K.; Goodwin, J. T.; Crivori, P.; Orrenius, C.; Xing, L.; Tandler, P. J.; Vidmar, T. J.; Amore, B. M.; Wilson, A. G. E.; Stouten, P. F. W.; Burton, P. S. Influence Of Molecular Flexibility And Polar Surface Area Metrics On Oral Bioavailability In The Rat J. Med. Chem. 2004, 47, 6104-6107 10.1021/jm0306529
262. Tian, S.; Li, Y.; Wang, J.; Zhang, J.; Hou, T. ADME Evaluation In Drug Discovery. 9. Prediction Of Oral Bioavailability In Humans Based On Molecular Properties And Structural Fingerprints Mol. Pharmaceutics 2011, 8, 841-851 10.1021/mp100444g
263. Meanwell, N. E. Synopsis Of Some Recent Tactical Application Of Bioisosteres In Drug Design J. Med. Chem. 2011, 54, 2529-2591 10.1021/jm1013693